Implementation of Physiotherapy on COVID-19 Patients in ICU

COVID-19 Clinical Trial

— PHYSIO-COVID  

Official title:

Implementation of Physiotherapy on COVID-19 Patients in Intensive Care Units : a Retrospective, Multicentric, International Study

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04347070
• Other study ID #: RECHMPL20_0175
• Status: Active, not recruiting
• Start date: April 1, 2017
• Est. completion date: December 1, 2022

Study information

• Verified date: December 2020
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Despite new charachersitics of COVID-19 patients, critical care implementation seems to be similar to those with Acute Respiratory Distress Syndrome (ARDS) in intensive care units (ICU).

Regarding the initial gravity of these patients, sedation and neuromuscular blockers are usually administrated, increasing the risk to develope an ICU-acquired weakness which is directly correlated to morbi-mortality and a burden during recovery.

Respiratory symptoms are mostly related to dyspnoea and non-productive cough, with only 33% of COVID-19 patient having a bronchial hypersecretion ; consequently, chest physiotherapy is only implemented in after case-by-case evaluation.

This unprecedented situation requires to identify how physiotherapy is being implemented in COVID-19 patients in ICU.

This retrospective, multicentric study aims to identify the charactheristics of physiotherapy (type and time spent) implemented in Argentina, Belgium, Chili, France, Italy and Spain

Description:

• Demographics data : hospitalisation date, ICU date, COVID+ date, extubation date, discharge date, mortality

• ICU data : ventilatory mode, type of physiotherapy implemented (early rehabilitation, chest physiotherapy, time spent (minutes), number of interventions per day.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 150
• Est. completion date: December 1, 2022
• Est. primary completion date: September 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Age > 18 years

• Patient admitted in ICU

• Patient with COVID-19 diagnosis

Exclusion criteria:

• Explicite denie to participate in the study

Related Conditions & MeSH terms

• COVID-19
• Sars-CoV2

Intervention

Other:
• Phsyiotherapy
To observe if patients with COVID-19 benefice of physiothersapy, which kind and how many time

Locations

Country	Name	City	State
France	Uhmontpellier	Montpellier

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital, Montpellier	Société espagnole de pneumologie (SEPAR), Societe française de kinésithérapie en réanimation (SKR)

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time of physiotherapy	Time of physiotherapy (minutes)	1 day
Primary	Time of physiotherapy	Time of physiotherapy (minutes)	3 day
Primary	Time of physiotherapy	Time of physiotherapy (minutes)	7 day
Secondary	Type of physiotherapy implemented	Type of physiotherapy , early rehabilitation or chest phsyitoherapy	1 day
Secondary	Type of physiotherapy implemented	Type of physiotherapy , early rehabilitation or chest phsyitoherapy	3 day
Secondary	Type of physiotherapy implemented	Type of physiotherapy , early rehabilitation or chest phsyitoherapy	7 day